JAN (JAN) Stock Price, News & Analysis

Company Overview

JanOne Inc. (NYSE: JAN) is a publicly traded company focused on addressing the opioid crisis through the development and commercialization of solutions intended to improve the treatment and prevention of opioid use disorder. The company has described its mission as combining business, technology and scientific initiatives to help reduce opioid-related harm.

JanOne’s activities have included biotechnology and pharmaceutical-development initiatives, as well as investments in technologies and businesses connected with healthcare and financial services. Its portfolio and operating focus have evolved over time as the company has pursued products and partnerships that support its broader goal of combating opioid addiction.

The company is headquartered in the United States and has been associated with international business activities through its subsidiaries and partners. Specific details regarding its current product pipeline, geographic operations and leadership may change as JanOne continues to develop its business.

Key Stats

• Today's Range: $28.76 to $29.21
• 50-Day Range: $27.79 to $31.83
• 52-Week Range: $22.76 to $32.83
• Volume: 661,466 shs
• Average Volume: 1.47 million shs
• Market Capitalization: $8.45 billion
• P/E Ratio: N/A
• Dividend Yield: 1.97%
• Price Target: $32.38
• Consensus Rating: Moderate Buy

JAN Stock Analysis - MarketRank™

JAN scored higher than 69% of companies evaluated by MarketBeat, and ranked 83rd out of 185 stocks in the real estate sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.4 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

JAN has received a consensus rating of Moderate Buy. The company's average rating score is 2.94, and is based on 2 strong buy ratings, 12 buy ratings, 3 hold ratings, and no sell ratings.

Upside Potential

JAN has a consensus price target of $32.38, representing about 11.5% upside from its current price of $29.04.

Amount of Analyst Coverage

JAN has been the subject of 12 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 1.9 / 5
• Proj. Earnings Growth: 23.71%

Earnings Growth

Earnings for JAN are expected to grow by 23.71% in the coming year, from $0.97 to $1.20 per share.

Price to Earnings Growth Ratio

JAN has a PEG Ratio of 1.11. PEG Ratios above 1 indicate that a company could be overvalued.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

3.91% of the float of JAN has been sold short.

Short Interest Ratio / Days to Cover

JAN has a short interest ratio ("days to cover") of 4.68.

Change versus previous month

Short interest in JAN has recently increased by 36.48%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 1.7 / 5
• Dividend Strength: Weak

Dividend Yield

JAN pays a meaningful dividend of 2.02%, higher than the bottom 25% of all stocks that pay dividends.

Dividend Growth

JAN does not have a long track record of dividend growth.

Dividend Sustainability

Based on earnings estimates, JAN will have a dividend payout ratio of 47.50% next year. This indicates that JAN will be able to sustain or increase its dividend.

News and Social Media

• Score: 3.6 / 5
• News Sentiment: 1.74

News Sentiment

JAN has a news sentiment score of 1.74. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.63 average news sentiment score of Real Estate companies.

News Coverage This Week

MarketBeat has tracked 59 news articles for JAN this week, compared to 18 articles on an average week.

Search Interest

Only 2 people have searched for JAN on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

MarketBeat Follows

Only 1 people have added JAN to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days.

Company Ownership

• Score: 0.1 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, JAN insiders have not sold or bought any company stock.

Percentage Held by Institutions

6.27% of the stock of JAN is held by institutions.

Company Calendar

• Last Earnings: 8/04/2026
• Today: 10/13/2026
• Record date for 10/28 Dividend: 10/16/2026
• Ex-Dividend for 10/28 Dividend: 10/16/2026
• Dividend Payable: 10/28/2026
• Next Earnings (Confirmed): 11/02/2026
• Record date for 11/23 Dividend: 11/12/2026
• Ex-Dividend for 11/23 Dividend: 11/12/2026
• Dividend Payable: 11/23/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NYSE
• Sector: Real Estate
• Industry: Healthcare REITs
• Sub-Industry: Healthcare REITs
• Current Symbol: NYSE:JAN
• CIK: 2100805
• Web: janusreit.com
• Phone: (720) 428-5050
• Fax: N/A
• Employees: 5
• Year Founded: N/A

Price Target and Rating

• Average Price Target for JAN: $32.38
• High Price Target: $37.00
• Low Price Target: $27.00
• Potential Upside/Downside: +11.6%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.94
• Research Coverage: 17 Analysts

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: 29.90
• P/E Growth: 1.11
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 5.46
• Quick Ratio: 5.46

Sales & Book Value

• Annual Sales: $603.99 million
• Price / Sales: 14.01
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 291,890,000
• Free Float: N/A
• Market Cap: $8.46 billion
• Optionable: N/A
• Beta: N/A